ArticleJournal of molecular medicine (Berlin, Germany)2025
4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia and a significant contributor to stroke occurrence. Although 4-Hydroxychalcone (4HCH) has notable anti-inflammatory and antioxidant properties, playing critical therapeutic roles in hypertensive nephropathy and cardiac remodeling, its effects on AF are somewhat unclear, thus forming the basis of this study. Herein, AF was induced in mice via continuous infusion of Angiotensin II (Ang II) at a dose of 2000 ng/kg/min for three weeks. The atrial diameter was assessed through echocardiography, while pathological staining was employed to evaluate atrial inflammation, Oxidative Stress (OS), and fibrosis. Compared to vehicle-treated controls, treatment with 4HCH significantly lowered both the incidence and duration of Ang II-induced AF, while also mitigating atrial dilation, inflammation, OS, and fibrosis. Mechanistically, 4HCH suppressed Ang II-induced immunoproteasome activity, including that of its catalytic subunits (β1i, β2i, and β5i), thus blocking the inflammatory IKKα/β-NF-κB signaling pathway. This inhibition downregulated the TGF-β1/Smad2/3 pathway and the potassium ion channel protein Kir 2.1, while upregulating connexin 40 (Cx40) and Cx43, thus mitigating atrial fibrosis and fibrillation. Conversely, the proteasome activator MK-886 increased both immunoproteasome expression and activity, triggering the IKKα/β-NF-κB pathway and leading to atrial inflammation, thus negating 4HCH's protective effects against Ang II-induced atrial remodeling and fibrillation. Overall, 4HCH may confer protective effects against AF, highlighting its potential as a therapeutic candidate for preventing the condition. KEY MESSAGES: 4-Hydroxychalcone (4HCH) confers protection against atrial fibrillation (AF) induced by angiotensin II. 4HCH attenuates the expression and activity of immunosubunits, resulting in the inhibition of IKK-NF-κB signaling and its downstream pathways. Increased activity of the immunoproteasome diminishes the beneficial effects of 4HCH on atrial remodeling and the prevention of AF.
Indexed as
Identifiers
40828375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.